comparemela.com

Latest Breaking News On - Chris anzalone - Page 8 : comparemela.com

Arrowhead Pharmaceuticals, Inc (ARWR) CEO Christopher Anzalone on Q2 2022 Results - Earnings Call Transcript

Arrowhead Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ARWR) Q2 2022 Earnings Conference Call May 10, 2022, 04:30 PM ET Company Participants Vince Anzalone - VP, IR Christopher Anzalone - President.

Arrowhead Pharmaceuticals, inc (ARWR) Q4 2021 Earnings Call Transcript

GSK joins NASH chase, paying $120M up front for rights to Arrowhead RNAi drug

GlaxoSmithKline sees enough promise in the early clinical data of a novel NASH drug to pay its developer, Arrowhead Pharmaceuticals, $120 million up front for rights to the experimental therapy. The Arrowhead drug uses RNA interference to “silence” an enzyme associated with the progression of the fatty liver disease.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.